Abstract: The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.

Abstract: The present invention relates to a process for the arylation of olefins by reaction of haloaromatics or arylsulfonates with olefins in the presence of a palladium catalyst, a bulky nitrogen base and a dipolar aprotic solvent.

Abstract: The present invention relates to a process for the arylation of olefins by reaction of haloaromatics or arylsulfonates with olefins in the presence of a palladium catalyst, a bulky nitrogen base and a salt.

Abstract: The invention relates to a process for preparing salts of dialkylphosphinic acids, which comprises a) reacting alkylphosphonous and/or hypo- phosphorous acid and/or alkali metal salts thereof with olefins in the presence of a free-radical initiator to give dialkylphosphinic acids and/or alkali metal salts thereof and b) reacting the dialkylphosphinic acids and/or alkali metal salts thereof obtained according to a) with metal compounds of Mg, Ca, Al, Sb, Sn, Ge, Ti, Zn, Fe, Zr, Ce, Bi, Sr, Mn, Li, Na and/or K to give the metal dialkyl20 phosphinate salts.

Abstract: The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or both, e.g., in a subject in need thereof, using a compound or formulation of the present invention. The present invention also relates to methods of treating a subject suffering from a chronic or acute disease, malady or condition due at least in part to an abnormality in the activity of an endogenous metabotropic glutamate receptor or a NAALADase enzyme or both, using a compound or formulation of the present invention.

Abstract: The invention concerns compounds derived from (&agr;-aminophosphino) peptides, of general formula (I), in which R1 and R2 each represents a hydrogen atom or taken together form an imine with the adjacent nitrogen atom; R3 represents an alkyl group, an alkenyl group, a phenyl group, a benzyl group, all these groups capable of being substituted or not, a hydrogen atom, a cycloalkyl group, a cycloalkylmethyl group or finally, a methyl group substituted by a heterocyclic, aromatic or saturated group; R4 represents a phenyl group, a benzyl group, these groups capable of being substituted or not, a hydrogen atom, an alkyl group, analkenyl group or a cycloalkyl group; R5 represents an alkyl group, an alkenyl group, a phenyl group, a benzyl group, all these groups capable of being substituted or not, a hydrogen atom, a cycloalkyl, cycloalkylmethyl group or finally a methyl group substituted by a heterocyclic, aromatic or saturated group; R6, R7 and R8 can in particular represent a hydrogen atom, an alkyl group, a phe

Abstract: The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or both, e.g., in a subject in need thereof, using a compound or formulation of the present invention. The present invention also relates to methods of treating a subject suffering from a chronic or acute disease, malady or condition due at least in part to an abnormality in the activity of an endogenous metabotropic glutamate receptor or a NAALADase enzyme or both, using a compound or formulation of the present invention.

Abstract: Novel thyroid receptor ligands are provided which have the general formula (I) where R1 is alkyl of 1 to 4 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 3 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen; n is an integer from 0 to 4; R4 is an aliphatic hydrocarbon, an aromatic hydrocarbon, carboxylic acid ester thereof, alkenyl carboxylic acid or ester thereof, hydroxy, halogen, cyano, or a phosphonic acid or an ester thereof, or a pharmaceutically acceptible salt thereof. A method for treating diseases associated with metabolism dysfunction or which are dependent on the expression of a T3 regulated gene, such as obesity, hypercholesterolemia, osteoporosis, hypothyroidism, and goiter, is also provided.

Abstract: Disclosed are methods for the dealkylation of phosphonate esters by use of trimethylchlorosilane as the dealkylating agent. In particular, this invention is directed to the discovery that high yields for the dealkylation of phosphonate esters can be achieved within relatively short reaction times by the use of trimethylchlorosilane provided that the dealkylation procedure occurs in a sealed vessel containing a compatible solvent.

Abstract: The present invention is directed to novel water-soluble prodrugs of aliphatic or aromatic hindered hydroxyl group containing pharmaceuticals.

Abstract: One aspect of the present invention relates to optionally substituted halogenated benzyl halides and the like. These compounds are useful as halogenated benzyl ether-based protecting groups for a variety of functional groups. Another aspect of the present invention relates to use of said protecting groups in an orthogonal protecting group strategy for the synthesis of complex molecules that comprise a number of suitable functional groups. Another aspect of the present invention relates to saccharides bearing various arrays of protecting groups of the present invention. Another aspect of the present invention relates to a method of synthesizing an oligosaccharide or glycoconjugate, comprising the steps of: using a saccharide bearing at least one protecting group of the present invention to glycosylate a second molecule to give a product comprising said saccharide; and removing a protecting group of the present invention from said product.

Abstract: The present invention relates to a process for the preparation of alkylphosphonic acids, which comprises reacting phosphorous acid (H3PO3) with short-chain olefins, and to the use of the products prepared by this process.

Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme.

Abstract: The present invention provides a novel ammonium salt of an organic acid. When the salt is used as a base additive for a chemically amplified resist, the environmental stability of the resist can be enhanced, and the T-top phenomenon can be effectively prevented. In addition, the line width change caused by acid diffusion can be prevented, and the E0 value of the resist can be decreased.

Abstract: A process for preparing polymerizable biaryl derivatives comprises reacting an aromatic comprising a 6-membered ring which bears ester or benzylic OH groups in the 1,4 position with a second aromatic in a palladium-catalyzed cross-coupling reaction to give a biaryl and converting the ester or benzylic OH groups into polymerizable groups in one or more steps. The biaryls obtained are suitable for preparing polymers which are used as electroluminescence materials.

Abstract: Aluminum salts of phosphinic acid or diphosphinic acids having alkyl and/or aryl substitutes, obtainable by heating an ester of the corresponding phosphinic acids or diphosphinic acids with aluminum hydroxide at a temperature of more than 150° C. under pressure in the presence of water, are distinguished by a particular crystal structure and are suitable as flameproofing agents for plastics.

Abstract: The invention relates to a process for preparing ethanebis(methylphosphinic) acid which comprises reacting ethyne (acetylene) with methyl phophonous acid.

Abstract: Diphosphonates or their salts between acids and linear, branch substituted and non-substituted, cyclic, heterocyclic and aromatic amino alcohols are used to treat osteoporosis. Pharmaceutical compositions and therapeutic methods of treating osteoporosis are described.

Abstract: Disclosed is quaternary ammonium phosphate compound having formula (1) and which has an anticorrosive and a biocidal efffect to have a capability of preventing corrosion of various metals including corrosive metal substances, e.g. carbon steels, iron casts, stain steels, coppers, tinning steel plates or alumina and an efficient method of preparing the same. In formula (1), R1 is a straight or a branched alkyl or aryl radical with 1 to 27 carbon atom(s) free of —OH group and may contain hereto-atoms, and both R2 and R3 are methyl groups or R2 and R3 are combined to form a heterocyclic compound with 4 to 6 of carbon atoms containing oxygen and nitrogen.

Abstract: The present invention relates to a process for the preparation of phosphinic acids from alkali metal phosphinates, which comprises reacting alkali metal phosphinates in a polar solvent with an inorganic mineral acid and then separating off the phosphinic acid formed.

Abstract: By forming a copper salt of phytic acid at a molar ratio of copper ion (Cu2+) to phytic acid of 2:1 or higher, there is provided a compound absorbing near infrared rays, which does not substantially absorb lights of visible light wavelength range, but strongly absorb lights of near infrared wavelength range, and shows extremely good water solubility.

Abstract: A single-stage method for producing &agr;-hydroxy ethers by oxidizing olefinic substrates with organic hydroperoxides and opening the resultant oxirane ring by means of monovalent or polyvalent alcohols wherein a molybdenum compound in combination with a compound selected from the group consisting of boron trifluoride, aluminum oxides, 1,8-diazabicyclo-[5.4.0]-undec-7-ene or 1,4-diazabicyclo-[2.2.2]-octane, and mixtures thereof is used as a catalyst system.

Abstract: The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel methods of using phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives to inhibit N-Acetylated &agr;-Linked Acidic Dipeptidase (NAALADase) enzyme activity, and to treat prostate diseases, especially using the compounds of the present invention for the inhibition of the growth of prostate cancer cells.

Abstract: The invention relates to a process for the preparation of dialkylphosphinic acids and salts thereof, which comprises a) reacting elemental yellow phosphorus with alkylating agents in the presence of a base to give a mixture which comprises, as principal constituents, the (metal) salts of alkylphosphonous, phosphorous and hypophosphorous acids, b) esterifying the principal constituents of the mixture from a) to give an ester mixture, c) isolating the ester of the alkylphosphonous acid from the ester mixture, d) preparing the corresponding ester of the dialkylphosphinic acid from the ester of the alkylphosphonous acid by free-radical-initiated reaction with olefins, e) converting the ester of the dialkylphosphinic acid into the free acid or into the dialkylphosphinic acid salts of metals from groups IA, IIA, IIIA, IVA, VA, IIB, IVB, VIIB or VIIIB of the Periodic Table or of cerium.

Abstract: A propionic acid derivative having the following formula (II) and its salt: 1

Abstract: The invention relates to a process for preparing salts of dialkylphosphinic acids, which comprises a) reacting alkylphosphonous and/or hypophosphorous acid and/or alkali metal salts thereof with olefins in the presence of a free-radical initiator to give dialkylphosphinic acids and/or alkali metal salts thereof and b) reacting the dialkylphosphinic acids and/or alkali metal salts thereof obtained according to a) with metal compounds of Mg, Ca, Al, Sb, Sn, Ge, Ti, Zn, Fe, Zr, Ce, Bi, Sr, Mn, Li, Na and/or K to give the metal dialkylphosphinate salts. The invention likewise relates to the use of the metal dialkylphosphinate salts prepared by the process according to the invention for preparing flame retardants.

Abstract: This invention relates to novel highly functionalized phosphine ligands as ancillary ligands in radiopharmaceuticals. Also, this invention provides radiopharmaceuticals comprised of highly functionalized phosphine ligated 99mTc labeled HYNIC-conjugated biomolecules that selectively localize at sites of disease and thus allow an image to be obtained of the loci using gamma scintigraphy. The invention also provides methods of use of the radiopharmaceuticals as imaging agents for the diagnosis of cardiovascular disorders such as thromboembolic disease or atherosclerosis, infectious disease and cancer.

Abstract: The invention relates to a process for preparing dialkylphosphinic acids and/or alkali metal salts thereof by reacting olefins with alkylphosphonous and/or hypophosphorous acid and/or alkali metal salts thereof, which comprises carrying out the reaction in the presence of a azo free-radical initiator. The invention also relates to the use of the products prepared by the abovementioned process for preparing flame retardants.

Abstract: This invention relates to water soluble phosphines of the following structural formula and method of preparing these phosphines: Wherein A is a moiety which is stable to the reaction conditions and does not interfere with solubility of the compound in the preparation reaction. R1 and R2 are selected from hydroxyl groups, dialkylamino group, and alkoxide groups.

Abstract: The invention relates to a process for preparing dialkylphosphinic acids and/or alkali metal salts thereof by reacting olefins with alkylphosphonous and/or hypophosphorous acid and/or alkali metal salts thereof, which comprises carrying out the reaction in the presence of a free-radical initiator. The invention also relates to the use of the products prepared by the abovementioned process for preparing flame retardants.

Abstract: New hydrate forms of alendronate sodium, having water content of between about one and about twelve percent, and processes for their manufacture, are disclosed. New crystalline forms of alendronate sodium B, D, E, F, G and H, and processes for manufacturing them, are also disclosed. These new forms of alendronate sodium are suitable for incorporation into pharmaceutical compositions for combating bone resorption in bone diseases.

Abstract: The present invention relates to a process for the preparation of phosphinic acid esters, which comprises a) reacting elemental yellow phosphorus with alkylating agents in the presence of a base to give a mixture which comprises, as principal constituents, the (metal) salts of alkylphosphonous, phosphorous and hypophosphorous acids, b) esterifying the principal constituents of the mixture from a) to give an ester mixture, c) isolating the ester of the alkylphosphonous acid from the ester mixture, d) adding the resultant ester of the alkylphosphonous acid onto an olefin containing a functional group. The invention likewise relates to the use of the phosphinic acid esters prepared by this process, inter alia as flame retardants and precursors for further syntheses.

Abstract: Formylphosphonic acid derivatives are prepared by the catalytic decomposition of a (phosphonomethyl)amine N-oxide compound to form the formylphosphonic acid derivative and a dephosphonomethylated amine.

Abstract: The invention relates to a process for preparing salts of dialkylphosphinic acids, which comprises a) reacting alkylphosphonous and/or hypophosphorous acid and/or alkali metal salts thereof with olefins in the presence of a free-radical initiator to give dialkylphosphinic acids and/or alkali metal salts thereof and b) reacting the dialkylphosphinic acids and/or alkali metal salts thereof obtained according to a) with metal compounds of Mg, Ca, Al, Sb, Sn, Ge, Ti, Zn, Fe, Zr, Ce, Bi, Sr, Mn, Li, Na and/or K to give the metal dialkylphosphinate salts. The invention likewise relates to the use of the metal dialkylphosphinate salts prepared by the process according to the invention for preparing flame retardants.

Abstract: Stable, enzymatically triggered chemiluminescent 1,2-dioxetanes with improved water solubility and storage stability are provided as well as synthetic processes and intermediates used in their preparation. Dioxetanes further substituted with two or more water-solubilizing groups disposed on the dioxetane structure and an additional fluorine atom or lower alkyl group provide superior performance by eliminating the problem of reagent carryover when used in assays performed on capsule chemistry analytical systems. These dioxetanes display substantially improved stability on storage. Compositions comprising these dioxetanes, a non-polymeric cationic surfactant enhancer and optionally a fluorescer, for providing enhanced chemiluminescence are also provided.

Abstract: The present invention relates to the preparation and biological activity of 3-deoxy-D-myo-inositol ether lipid analogs as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. The compounds of the present invention are useful as anti-tumor agents which effectively inhibit the growth of mammalian cells.

Abstract: The invention relates to a process for preparing arylalkyiphosphinic acids and/or alkali metal salts thereof by reacting olefins with arylphosphonous acids and/or alkali metal salts thereof, which comprises carrying out the reaction in the presence of a free-radical initiator. The invention also relates to the use of the products prepared by the abovementioned process for preparing flame retardants.

Abstract: The present invention relates to novel geranylgeranyl derivatives and the pharmaceutically acceptable salts thereof having antiproliferative activity in eukaryotic cells with respect to the inhibition of protein geranygeranylation. The invention also relates to the pharmaceutical compositions containing the novel derivatives and to the process of preparation thereof.

Abstract: The invention concerns aromatic tetralcyclic compounds of the retinoid type of general formula (I). The invention also concerns the method for preparing them and the pharmaceutical compositions containing at least one of said compounds.

Abstract: The invention relates to a process for preparing metal salts of arylalkylphosphinic acids, which comprises: a) reacting olefins with arylphosphonous acids or alkali metal salts thereof in the presence of a cationic free-radical initiator, and b) reacting the arylalkylphosphinic acids or alkali metal salts thereof obtained by a) with metal compounds of Mg, Ca, Al, Sb, Sn, Ge, Ti, Zn, Fe, Zr, Ce, Bi, Sr, Mn, Li, Na and/or K to give the metal arylalkylphosphinate salts. The invention also relates to the use of the products prepared by the abovementioned process for preparing flame retardants.

Abstract: Aluminum salts of alky-(1-alkoxyethyl)phosphinic acids are prepared by reacting alky-(1-alkoxyethyl)phospihnic acids with aluminum hydroxide in a molar ratio of 3:1. The resulting aluminum phosphinates are used as flame retardants in thermoplastics, particularly in polyesters.

Abstract: A method for the preparation of alkene phosphonic acids and salts thereof, such as VDPA (vinylidene diphosphonic acid) is disclosed. The products can be produced in a stable, substantially pure form and in high yield. The method includes the azeotropic removal of water from salts of &agr;-hydroxy-alkane diphosphonic acid dimer or corresponding acids thereof, and the pyrolysis of the dehydrated reactant at a temperature of from 170° C. to 300° C. There may be included a step to convert anhydrides which have been formed during the pyrolysis. The method may include the use of heat transfer agents and/or bases, and may be carried out at elevated or reduced pressure.

Abstract: Aluminum salts of phosphinic acid or diphosphinic acids having alkyl and/or aryl substitutes, obtainable by heating an ester of the corresponding phosphinic acids or diphosphinic acids with aluminum hydroxide at a temperature of more than 150° C. under pressure in the presence of water, are distinguished by a particular crystal structure and are suitable as flameproofing agents for plastics.

Abstract: A novel process for the preparation of alendronic acid is disclosed. The method comprises the steps of reacting a compound of formula I with H3PO3 wherein R is an imido group and R1 is selected from the group consisting of chloro, bromo, iodo, fluoro, hydroxy, amino, —OR2 or —OC(O)R2, wherein R2 is C1-C12 alkyl, C1-C12 cycloalkyl or C1-C12 aryl; and then reacting the product of the first step with a deprotecting agent. Alendronic acid is then recovered. The method is safe, efficient and suitable for use on a large scale.

Abstract: A process for the manufacture of phosphorous acid by selective hydrolysis of phosphite esters. A hydrolysis feed mixture comprising phosphite esters and phosphate esters is contacted with liquid water or steam to selectively hydrolyze the phosphite esters to phosphorous acid. The feed mixture may be prepared by oxidation of elemental phosphorous in the presence of an alcohol. In the oxidation and/or a subsequent esterification step, P(III) and P(V) oxyacids produced in the oxidation reaction are esterified, preferably quantitatively. The ester mixture may be washed to remove unesterified phosphoric and hypophosphorous acid, after which the selective hydrolysis is carried out.

Abstract: A process for preparing aluminum salts (I) of dialkylphosphinic acids or (formula (II)) of alkylated diphosphinic acids where R1 and R2 are a linear or branched C1-C8-alkyl radical and R3 is a linear or branched C1-C10-alkylene radical or an arylene radical or an alkylarylene radical or an arylalkylene radical, which comprises reacting a dialkylphosphinic acid ester of the formula (III) or a diphosphinic acid ester of the formula (IV) where R1, R2 and R3 are as defined above and R4 is a linear or branched C1-C8-alkyl radical, in the presence of a saturated aliphatic monocarboxylic acid having a total of from 1 to 7 carbon atoms, with aluminum hydroxide at a temperature of from 150 to 350° C.

Abstract: Hydrolysis-stable and polymerizable acrylphosphonic acids are described which are particularly suitable as a component of dental adhesives owing to their adhesion-promoting properties.

Abstract: An electrode for detecting interactions between members of a binding pair, which electrode has been modified by formation of a non-conductive self-assembled monolayer, and a method of detecting biomolecules, such as nucleic acids or other targets, including receptors, ligands, antigens or antibodies, utilizing such an electrode. When contacted with a target nucleic acid, an oligonucleotide probe coupled to the self-assembled monolayer reacts with the target nucleic acid to form a hybridized nucleic acid on the modified electrode surface. The hybridized nucleic acid is reacted with a transition metal complex capable of oxidizing a preselected base in the hybridized nucleic acid in an oxidation-reduction reaction, the oxidation-reduction reaction is detected, and the presence or absence of the nucleic acid is determined from the detected oxidation-reduction reaction.

Abstract: This invention relates to a method for producing aluminum phosphinates of the formula [R.sub.1 R.sub.2 P(O)O.sup.- ].sub.3 Al.sup.3 +, where R.sub.1 and R.sub.2 are the same or different and represent a C.sub.1-8 alkyl group or a phenyl group. The process involves reaction of the corresponding alkali metal phosphinate with aluminum sulfate. The aluminum phosphinate salts are useful as a flame retardant for plastics.

Abstract: The present invention relates to phosphorus-containing compounds based on 1-hydroxypropane-1,3-diphosphonic acid and to the acid itself of general formula (I) ##STR1## in which M.sup.1, M.sup.2, M.sup.3, M.sup.4 and M.sup.5, independently of one another, each denote a radical from the series hydrogen, alkali metal, an equivalent of ammonium, alkyl- or hydroxyalkyl-substituted ammonium,a process for the preparation thereof, novel intermediates and the use thereof as a corrosion inhibitor, scale inhibitor and as a flame retardant.